🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the battle against increasingly resistant strains of the bacteria, according to scientists.

A Global Health Concern

The sexually transmitted infection are on the rise globally, with data suggesting over 82 million new cases annually. Notably increased rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune development in the face of increasing worldwide cases, the spread of superbugs and the very limited therapeutic options presently on offer.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The global health body has designated it as a "critical concern". A tracking program revealed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Receive Clearance

One new antibiotic, also known as a brand name, was authorized by the American regulatory agency in mid-December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Scientists anticipate that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, originating from the drugmaker GSK, was also approved in close succession. This treatment, which is additionally indicated for urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to bring it to fruition.

“This milestone represents a major breakthrough in the treatment of highly resistant gonorrhoea, which previously has been outpacing antibiotic development.”

Research Study Data and Worldwide Availability

As per data published in a prominent scientific publication, the new drug eradicated the vast majority of cases of the STI. This puts it on an similar efficacy with the existing first-line therapy, which combines two antibiotics. The trial included hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians treating patients have expressed optimism. The availability of a one-pill regimen like this is described as a "critical tool" for gonorrhoea control. This is considered crucial to alleviate the strain of the illness for patients and to stop the proliferation of untreatable gonorrhoea worldwide.